following a full submission:
alectinib (Alecensa®) is accepted for use within NHSScotland.
Indication under review: as monotherapy as adjuvant treatment for adult patients with
Stage IB (tumours ≥ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic
lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete
tumour resection.
In an open-label phase III study, alectinib was associated with a statistically significant
improvement in disease-free survival compared with platinum-based chemotherapy
following surgery in patients with early ALK-positive NSCLC.
This advice applies only in the context of approved NHSScotland Patient Access Scheme
(PAS) arrangements delivering the cost-effectiveness results upon which the decision was
based, or PAS/ list prices that are equivalent or lower.
Medicine details
- Medicine name:
- alectinib hydrochloride (Alecensa)
- SMC ID:
- SMC2749
- Indication:
Monotherapy as adjuvant treatment for adult patients with Stage IB (tumours ≥ 4cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 April 2025